section name header

Pronunciation

byoo-toe-KON-a-zole

Classifications

Therapeutic Classification: antifungals (vaginal)

Indications

REMS


Action

  • Affects the permeability of the fungal cell wall, allowing leakage of cellular contents. Not active against bacteria.
Therapeutic effects:
  • Inhibited growth and death of susceptible Candida, with decrease in accompanying symptoms of vulvovaginitis (vaginal burning, itching, discharge).

Pharmacokinetics

Absorption: 2% is systemically absorbed following intravaginal administration.

Distribution: Unknown. Action is primarily local.

Metabolism/Excretion: Negligible with local application.

Half-Life: Not applicable.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
Intravaginalunknown12–24 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GU: itching, pelvic pain, soreness, swelling, vulvovaginal burning

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Gynazole-1